Novo Nordisk A/S (NYSE: NVO) is a leading global healthcare and pharmaceutical enterprise specializing primarily in life-saving diabetes care medications, obesity treatment therapeutics, rare blood disorder management, and hormone replacement therapies. Its flagship pharmaceutical innovations, including advanced GLP-1 receptor agonist treatments, have driven massive global demand and profound commercial expansion across international markets.